Literature DB >> 10198434

Combinatorial selection of high affinity RNA ligands to live African trypanosomes.

M Homann1, H U Göringer.   

Abstract

African trypanosomiasis is a parasitic disease caused by a specific class of protozoan organisms. The best-studied representative of that group is Trypanosoma brucei which is transmitted by tsetse flies and multiplies in the blood of many mammals. Trypanosomes evade the immune system by altering their surface structure which is dominated by a layer of a variant surface glycoprotein (VSG). Although invariant surface proteins exist, they are inaccessible to the humoral immune response. Using a combinatorial selection method in conjunction with live trypanosomes as the binding target, we show that short RNA ligands (aptamers) for constant surface components can be isolated. We describe the selection of three classes of RNA aptamers that crosslink to a single 42 kDa protein located within the flagellar pocket of the parasite. The RNAs associate rapidly and with high affinity. They do not discriminate between two different trypanosome VSG variant strains and, furthermore, are able to bind to other trypanosome strains not used in the selection protocol. Thus, the aptamers have the potential to function as markers on the surface of the extracellular parasite and as such they might be modified to function as novel drugs against African trypanosomiasis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10198434      PMCID: PMC148414          DOI: 10.1093/nar/27.9.2006

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  42 in total

1.  Mechanism of the gBP21-mediated RNA/RNA annealing reaction: matchmaking and charge reduction.

Authors:  Ulrich F Müller; H Ulrich Göringer
Journal:  Nucleic Acids Res       Date:  2002-01-15       Impact factor: 16.971

2.  A selection system for identifying accessible sites in target RNAs.

Authors:  W H Pan; H F Devlin; C Kelley; H C Isom; G A Clawson
Journal:  RNA       Date:  2001-04       Impact factor: 4.942

3.  Targeting the variable surface of African trypanosomes with variant surface glycoprotein-specific, serum-stable RNA aptamers.

Authors:  Mihaela Lorger; Markus Engstler; Matthias Homann; H Ulrich Göringer
Journal:  Eukaryot Cell       Date:  2003-02

Review 4.  Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.

Authors:  Khaled S Allemailem; Ahmad Almatroudi; Mohammed A Alsahli; Ghaiyda Talal Basfar; Faris Alrumaihi; Arshad Husain Rahmani; Amjad Ali Khan
Journal:  3 Biotech       Date:  2020-11-24       Impact factor: 2.406

5.  Combining SELEX and the yeast three-hybrid system for in vivo selection and classification of RNA aptamers.

Authors:  Julian König; Christian Julius; Sebastian Baumann; Matthias Homann; H Ulrich Göringer; Michael Feldbrügge
Journal:  RNA       Date:  2007-02-05       Impact factor: 4.942

Review 6.  Cell-specific aptamers for targeted therapies.

Authors:  Laura Cerchia; Paloma H Giangrande; James O McNamara; Vittorio de Franciscis
Journal:  Methods Mol Biol       Date:  2009

Review 7.  Molecular imaging with nanoparticles: giant roles for dwarf actors.

Authors:  Paul Debbage; Werner Jaschke
Journal:  Histochem Cell Biol       Date:  2008-09-30       Impact factor: 4.304

Review 8.  Designed and Evolved Nucleic Acid Nanotechnology: Contrast and Complementarity.

Authors:  Tulsi Ram Damase; Peter B Allen
Journal:  Bioconjug Chem       Date:  2019-01-03       Impact factor: 4.774

9.  Strategies for the discovery of therapeutic aptamers.

Authors:  Xianbin Yang; Na Li; David G Gorenstein
Journal:  Expert Opin Drug Discov       Date:  2011-01       Impact factor: 6.098

10.  RAID3--An interleukin-6 receptor-binding aptamer with post-selective modification-resistant affinity.

Authors:  Florian Mittelberger; Cindy Meyer; Georg H Waetzig; Martin Zacharias; Erica Valentini; Dmitri I Svergun; Katharina Berg; Inken Lorenzen; Joachim Grötzinger; Stefan Rose-John; Ulrich Hahn
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.